Results from three studies together suggest progress in identifying diet, supplementation, and gut microbiome signatures ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and ...

Paternal exposure to methotrexate before conception is not linked to increased risks for adverse birth outcomes, but ...

Rheumatoid arthritis (RA) may cause hair loss due to medications, other autoimmune diseases, or stress. Learn about the ...

Discover how early biologic therapy compares with standard care in psoriatic arthritis. Learn more about treatment strategies ...

The National Consumer Disputes Redressal Commission (NCDRC) recently directed a doctor from West Bengal to pay Rs 2.5 lakh to ...

Use of disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA) was markedly lower among all major ...

ALL is the most common childhood cancer, and cases are rising. Find out why this trend is paired with a remarkable 90% survival rate, and what public health action is needed next.

BSR’s updated csDMARD guideline introduces new evidence, whole-life-course recommendations, and risk-adaptive monitoring.

Alvotech and Advanz Pharma have announced the European Commission’s (EC) marketing authorisations for Gobivaz, a biosimilar to Simponi (golimumab), across the European Economic Area (EEA).

SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug ...